The FDA Unblocked This Drug Trial. Nasdaq May Delist the Company Anyway.
The FDA cleared Filana's simufilam program to advance to a human trial five days after Nasdaq put the company on notice for trading too low. Both clocks now run to early 2027.
ticker-flna
1 storyCoverage